Phase 3 non-inferiority RCT of 211 mostly postoperative ventilated ICU patients: remimazolam tosylate was non-inferior to propofol for sedation success (98.1% vs 96.2%; difference 1.9%, margin -8%). Adverse events 76.4% vs 73.3%, mostly mild-moderate.
RCTn = 211
Guan et al. Efficacy and Safety of Remimazolam Tosylate versus Propofol for Sedation of Postoperative Mechanically Ventilated Patients in Intensive Care Units: A Multicenter, Randomized, Single-blind, Noninferiority, Phase 3 Trial